Expert Outlook: Scott Schliebner on the Future of Clinical Trials in 2025
As featured in Scrip | “Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends” | By Eleanor Malone | Published: February 6, 2025
Scott Schliebner, Vice President and Global Head of Drug Development Consulting at Novotech, offers a forward-looking perspective on how clinical trials are evolving in 2025. In an expert roundup published by Scrip, Schliebner outlines how data science, adaptive trial models, and real-world evidence (RWE) will shape a new era of clinical development.
Key Takeaways from Scott Schliebner:
AI-Led Trial Transformation
Schliebner predicts that by 2025, artificial intelligence will manage 50% of trial data tasks, cutting timelines by 20% and improving data precision. This AI-driven efficiency will enable faster insights and decision-making in complex global trials.
Expanding Use of Real-World Evidence (RWE)
He forecasts that over 85% of pharmaceutical companies will adopt RWE to support more inclusive trial designs, ensuring broader demographic representation and better-informed therapeutic strategies.
Adaptive and Biomarker-Driven Models
According to Schliebner, adaptive trial methodologies and biomarker-focused approaches will become standard, allowing for more personalized, efficient development paths and improved patient outcomes.
Blockchain for Data Integrity
Highlighting the need for security and transparency, Schliebner predicts blockchain technology will play a pivotal role in safeguarding trial data, ensuring auditability and trust throughout the study lifecycle.
“These advancements will shape a future where trials are faster, more inclusive, and precision-driven, ultimately accelerating the development of innovative therapies and improving global healthcare outcomes,” — Scott Schliebner, Novotech
As clinical trials become more technologically enabled and patient-centric, Schliebner’s insights reflect Novotech’s continued leadership in integrating innovation and operational excellence to support biotech sponsors navigating the future of global drug development.